Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 4, 2003, Pages 426-438

  Sabbaj, Steffanie ^a,f   Bansal, Anju ^a   Ritter, G Douglas ^a   Perkins, Christopher ^a   Edwards, Bradley H ^a   Gough, Ethan ^a   Tang, Jianming ^c   Szinger, James J ^e   Korber, Bette ^e   Wilson, Craig M ^a,d   Kaslow, Richard A ^a,b,c   Mulligan, Mark J ^a,b   Goepfert, Paul A ^a,b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

CD8 T cell responses; Class I restriction; CTL epitopes; CTL vaccines; HIV vaccine

Indexed keywords

CD8 ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ANTIGEN SPECIFICITY; ARTICLE; CELL KILLING; COHORT ANALYSIS; DRUG CROSS REACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MINORITY GROUP; PRIORITY JOURNAL; RACE DIFFERENCE; SEROCONVERSION; T LYMPHOCYTE ACTIVATION;

EID: 0037961092     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308010-00003     Document Type: Article

References (76)

1. AVEG. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J lnfect Dis. 2001;183: 563-570.
2. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331-335.
3. McMichael AJ, Hanke T. Is an HIV vaccine possible? Nat Med. 1999;5:612-614.
4. Borrow P, Hanna L, Wei Z, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997;3:205-211.
5. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68:4650-4655.
6. Edwards BH, Bansal A, Sabbaj S, et al. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol. 2002;76:2298-2305.
7. Kostense S, Ogg GS, Manting EH, et al. High vital burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol. 2001; 31:677-686.
8. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103-2106.
9. Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest. 1998;102:1758-1765.
10. Kaul R, Plummer FA, Kimani J, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol. 2000;164:1602-1611.
11. Kaul R, Dong T, Plummer FA, et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest. 2001;107:1303-1310.
12. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857-860.
13. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-998.
14. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292:69-74.
15. Barouch DH, Santra S, Kuroda MJ, et al. Reduction of simian-human immunodeficiency virus 89.6p viremia in rhesus monkeys by recombinant modified vaccinia virus ankara vaccination. J Virol. 2001;75:5151-5158.
16. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000;290:486-492.
17. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A. 1997;94:1396-1401.
18. Cao H, Mani I, Vincent R, et al. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis. 2000;182:1350-1356.
19. Dorrell L, Willcox BE, Jones EY, et al. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.PG-1747-56. Eur J Immunol. 2001;31.
20. Ferrari G, Neal W, Jones A, et al. CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. Immunol Lett. 2001;79:37-45.
21. Tang J, Wilson CM, Meleth S, et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS. 2002;16:2275-2284.
22. Tang J, Tang S, Lobashevsky E, et al. Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. J Virol. 2002;76:8276-8284.
23. Cao K, Hollenbach J, Shi X, et al. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62:1009-1030.
24. Korber BT, Brander C, Haynes BF, et al. HIV Molecular Immunology 2001. Los Alamos, New Mexico: Los Alamos National Laboratory; 2001.
25. Pinto LA, Berzofsky JA, Fowke KR, et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS. 1999;13:2003-2012.
26. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41:178-228.
27. Rammensee HG. Antigen presentation - recent developments. Int Arch Allergy Immunol. 1996;110:299-307.
28. Shankar P, Sprang H, Lieberman J. Effective lysis of HIV-1-infected primary CD4+ T cells by a cytotoxic T-lymphocyte clone directed against a novel A2-restricted reverse-transcriptase epitope. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:111-120.
29. Sette A, Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol. 1998;10: 478-482.
30. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics. 1999;50:201-212.
31. Bansal A, Sabbaj S, Edwards B, et al. T cell responses and MHC class I genotypes in HIV-1-infected African American and Hispanic adolescents. AIDS Research and Human Retrovirus. 2003 (in press).
32. Brander C, Hartman KE, Trocha AK, et al. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest. 1998;101:2559-2566.
33. Goulder PJ, Sewell AK, Lalloo DG, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigen (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med. 1997;185:1423-1433.
34. Gray CM, Lawrence J, Schapiro JM, et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol. 1999; 162:1780-1788.
35. Goepfert PA, Bansal A, Edwards BH, et al. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol. 2000;74:10249-10255.
36. Goulder PJ, Altfeld MA, Rosenberg ES, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med. 2001;193:181-194.
37. Altfeld M, Addo MM, Eldridge RL, et al. Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol. 2001;167: 2743-2752.
38. Addo MM, Altfeld M, Rosenberg ES, et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A. 2001;98:1781-1786.
39. Alexander-Miller MA, Parker KC, Tsukui T, et al. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int Immunol. 1996;8:641-649.
40. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296:2354-2360.
41. Yusim K, Kesmir C, Gaschen B, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.PG-8757-68. J Virol. 2002;76.
42. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol. 2001;75:11983-11991.
43. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 2002;415:335-339.
44. Threlkeld SC, Wentworth PA, Kalams SA, et al. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. J Immunol. 1997;159:1648-1657.
45. Novitsky V, Cao H, Rybak N, et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol. 2002;76:10155-10168.
46. Novitsky V, Rybak N, McLane MF, et al. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol. 2001;75:9210-9228.
47. Yu XG, Addo MM, Rosenberg ES, et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol. 2002;76:8690-8701.
48. Propato A, Schiaffella E, Vicenzi E, et al. Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum Immunol. 2001;62:561-576.
49. van der Burg SH, Klein MR, Pontesilli O, et al. HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS. J Immunol. 1997;159:36483654.
50. Goulder PJ, Sewell AK, Lalloo DG, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med. 1997;185:1423-1433.
51. Goulder P, Price D, Nowak M, et al. Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol Rev. 1997;159:17-29.
52. Goulder PJ, Tang Y, Pelton SI, et al. HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other. J Virol. 2000;74:5291-5299.
53. Goulder PJ, Brander C, Annamalai K, et al. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and Caucasoid adults and children. J Virol. 2000;74:5679-5690.
54. Goulder PJ, Addo MM, Altfeld MA, et al. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J Virol. 2001;75:1339-1347.
55. Goulder PJ, Bunce M, Luzzi G, et al. Potential underestimation of HLA-C-restricted cytotoxic T-lymphocyte responses. AIDS. 1997; 11:1884-1886.
56. Rowland-Jones S, Dong T, Krausa P, et al. The role of cytotoxic T-cells in HIV infection. Dev Biol Stand. 1998;92:209-214.
57. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med. 2001;193:169-180.
58. Altfeld MA, Livingston B, Reshamwala N, et al. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol. 2001;75:1301-1311.
59. Altfeld MA, Trocha A, Eldridge RL, et al. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. J Virol. 2000;74: 8541-8549.
60. Shiga H, Shioda T, Tomiyama H, et al. Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS. 1996;10:1075-1083.
61. Kaul R, Rowland-Jones SL, Kimani J, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest. 2001;107:341-349.
62. Menendez-Arias L, Mas A, Domingo E. Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review). Viral Immunol. 1998;11:167-181.
63. Sipsas NV, Kalams SA, Trocha A, et al. Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J Clin Invest. 1997;99:752-762.
64. Tomiyama H, Sakaguchi T, Miwa K, et al. Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. Hum Immunol. 1999;60:177-186.
65. Samri A, Haas G, Duntze J, et al. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J Virol. 2000;74:9306-9312.
66. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000;97:3382-3387.
67. Mollet L, Li TS, Samri A, et al. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J Immunol. 2000;165:1692-1704.
68. Betts MR, Casazza JP, Patterson BA, et al. Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol. 2000;74:9144-9151.
69. Day CL, Shea AK, Altfeld MA, et al. Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J Virol. 2001;75:6279-6291.
70. Buseyne F, Fevrier M, Garcia S, et al. Dual function of a human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte clone: inhibition of HIV replication by noncytolytic mechanisms and lysis of HIV-infected CD4+ cells. Virology. 1996;225:248-253.
71. Buseyne F, Stevanovic S, Rammensee HG, et al. Characterization of an HIV-1 p24gag epitope recognized by a CD8+ cytotoxic T-cell clone. Immunol Lett. 1997;55:145-149.
72. Sutton J, Rowland-Jones S, Rosenberg W, et al. A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol. 1993;23:447-453.
73. Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest. 1998;102:1758-1765.
74. Lucchiari-Hartz M, van Endert PM, Lauvau G, et al. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J Exp Med. 2000;191:239-252.
75. Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasi-species in a person with prolonged infection and low viral load. J Immunol. 1996;156:2616-2623.
76. Couillin I, Culmann-Penciolelli B, Gomard E, et al. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J Exp Med. 1994;180:1129-1134.